Kelly MacDonald
  Kelly S. MacDonald MD FRCPC
H.E. Sellers Research Chair
Professor, Departments of Medicine, Microbiology & Immunology
Max Rady College of Medicine
University of Manitoba

Adjunct Scientist, JC Wilt Infectious Diseases Research Centre
Public Health Agency of Canada

Administrative Office:
Rm. 501, Basic Medical Sciences Building
University of Manitoba.
745 Bannatyne Ave.
Winnipeg, MB, R3E 0J9
Office 204 977 5680
Fax 204 789 3926

Administrative Assistant:
Sheila  Ang
Room 543, Basic Medical Sciences Building
University of Manitoba.
Tel No. 204.977.5681, Fax No. 204.789.3926

Clinical Interest:
• She practices mainly inpatient infectious diseases at the Health Sciences Centre in Winnipeg on the medical and surgical infectious diseases consultation services and takes after-hours call province-wide on the tele-heath system.  She is experienced with immunocompromised, oncological cases and bone marrow transplantation having practiced more than 10 years as a consultant at Princess Margaret Hospital and as consultant for the  biologic therapy program.
• Dr MacDonald also has particular expertise in the area of sexually transmitted infections from both a clinical and research standpoint with publications in a wide variety of bacterial and viral STI and sits on a number of public health advisory committees.
Research Interest:
• Dr MacDonald holds the HE Sellers Research Chair in the Department of Medicine and supervises a research laboratory at the JC Wilt Infectious Diseases Research Centre of the  Public Health Agency of Canada, where she is an adjunct scientist. She came to Winnipeg in 2015 from Toronto where she was previously the head of the HIV research program in the Department of Medicine.
• She has worked in the field of host immunity to HIV and its application in vaccine design for 25 years.  Over the years her work has moved from an initial examination of immunogenetic susceptibility to infectious diseases to in vitro and molecular studies of mechanisms by which cellular immune epitopes may act as decoys to prevent the emergence of more protective immune responses (ref 6). Studies in the SIV macaque challenge model have demonstrated that hyper-attenuated SIV causing abortive infection can induce long term non-progressive SIV infection subsequently (ref 5).
• More recently studies utilizing both Varicella Zoster Virus (VZV) and Cytomegalovirus (CMV) as Vaccine vectors for SIV/HIV vaccines in the Cynomolgus macaque model have been conducted, the former model demonstrating that effector immune responses against SIV can induce complete control of viral load and undetectable viral load in a significant portion of vaccines and overall significantly improved viral load. Therefore promising work in both models and a preliminary human trial are continuing ( ref 1-4)
• Other human clinical trials involving the examination of mucosal immunity and the interaction between HIV and other mucosal cofactors are ongoing in collaboration with colleagues at the Kenya AIDS Vaccine Initiative, Department of Microbiology, University of Nairobi.
• Dr MacDonald supervises graduate students through the University of Manitoba (Departments of Immunology, Medical Microbiology) and the University of Toronto (Department of Immunology).
Research Labs:
JC Wilt Infectious Diseases Research Centre, Winnipeg  Tel 204 789 6484
Rm 6360, Medical Sciences Bldg, University of Toronto, Toronto, Tel 416 946 3733

Current Research Team Members:
· Carolina Campos Lima Moreira Post-Doc Fellow (Immunology Lab, Apotex Centre)
· Elinor Shvartsman MSc Student (JC Wilt Lab)

For a list of Dr. MacDonald's PubMed articles, please click here

Selected Publications:

1. Perciani CT, Farah B, Kaul R, Ostrowski M, Mahmud SM, Anzala O, Jaoko W KAVI-ICR Team, MacDonald KS. Live-attenuated Varicella-zoster virus vaccine does not induce HIV target cell activation. Epub, J Clin Invest. 2018 Dec 15;129(2):875-886. DOI: 10.1172/JCI124473 (Trainee Publication). Senior Responsible Author. Significant Publication. I conceived and developed the clinical trial on which this is based and am responsible for the original hypothesis which underlies the concepts that VZV provides a unique type of effector memory which would be a beneficial HIV vaccine. This paper demonstrates that this vector is safe immunogenic and does not provoke significant mucosal immune activation 12 weeks post vaccination.

2. Perciani CT, Sekhon M, Hundal S, Farah B, Ostrowski MA, Anzala AO, McKinnon LR, UNITID Group, KAVI-ICR Team, Walter J, MacDonald KS. Live-attenuated Zoster Vaccine Boosts VZV-specific Humoral Responses Systemically and at the Cervico-vaginal Mucosa of Kenyan VZV-seropositive Women. J Infect Dis. 2018 Sep 8;218(8):1210-1218. (Trainee Publication. Catia Perciani). Senior Responsible Author. Significant Publication. This paper demonstrates that the VZV Vector which we propose to use for our VZV-HIV vaccine not only generates excellent systemic immune responses but for the first time, demonstrates mucosal immunity at the site that HIV would challenge them. I conceptualized the study, supervised the process including the graduate trainee first author and co-wrote the paper.

3. Perciani CT, Jaoko W, Farah B, Ostrowski MA, Anzala O, MacDonald KS; KAVI-ICR Team. αEβ7, α4β7 and α4β1 integrin contributions to T cell distribution in blood, cervix and rectal tissues: Potential implications for HIV transmission. PLoS One. 2018 Feb 8. eCollection 2018. (Trainee Publication. Catia Perciani). Senior Responsible Author. Significant Publication. This paper is the first to document that the rectum, cervico-vaginal and oral mucosal all have unique mucosal milieu, including a constellation of homing integrins which greatly impacts on their susceptibility to HIV infection. As senior author, I conceived the study supervised, and co-wrote the results.

4. Protocol of a randomised controlled trial characterising the immune responses induced by varicella-zoster virus (VZV) vaccination in healthy Kenyan women: setting the stage for a potential VZV-based HIV vaccine. Perciani CT, Jaoko W, Walmsley S, Farah B, Mahmud SM, Ostrowski M, Anzala O, Team KI, MacDonald KS. BMJ Open. 2017 Sep 21;7(9):e017391. doi: 10.1136/bmjopen-2017-017391.PMID:     28939581
5. Clinical and Mucosal Immune Correlates of HIV-1 Semen Levels in Antiretroviral-Naive Men. Osborne BJW, Marsh AK, Huibner S, Shahabi K, Liu C, Contente T, Nagelkerke NJD, Kovacs C, Benko E, Price L, MacDonald KS, Kaul R Open Forum Infect Dis. 2017 Feb 21;4(2):ofx033. doi: 10.1093/ofid/ofx033. eCollection 2017 Spring. PMID:28534034

6. A novel strain of cynomolgus macaque cytomegalovirus: implications for host-virus co-evolution. Russell JN, Marsh AK, Willer DO, Ambagala AP, Dzamba M, Chan JK, Pilon R, Fournier J, Brudno M, Antony JM, Sandstrom P, Evans BJ, MacDonald KS. BMC Genomics. 2016 Apr 5;17:277.

7. A critical analysis of the cynomolgus macaque, Macaca fascicularis, as a model to test HIV-1/SIV vaccine efficacy. Antony JM, MacDonald KS. Vaccine. 2015 Jun 17;33(27):3073-83

8. Examining the species-specificity of rhesus macaque cytomegalovirus (RhCMV) in cynomolgus macaques. Marsh AK, Ambagala AP, Perciani CT, Russell JN, Chan JK, Janes M, Antony JM, Pilon R, Sandstrom P, Willer DO, MacDonald KS. PLoS One. 2015 Mar 30;10(3):e0121339

9. Experimental infection of Cynomolgus Macaques (Macaca fascicularis) with human Varicella-Zoster Virus. Willer DO, Ambagala AP, Pilon R, Chan JK, Fournier J, Brooks J, Sandstrom P, Macdonald KS. J Virol. 2012 Apr;86(7):3626-34.

10. Multi-low-dose mucosal simian immunodeficiency virus SIVmac239 challenge of cynomolgus macaques immunized with "hyperattenuated" SIV constructs. Willer DO, Guan Y, Luscher MA, Li B, Pilon R, Fournier J, Parenteau M, Wainberg MA, Sandstrom P, MacDonald KS. J Virol. 2010 Mar;84(5):2304-17

11. Viral fitness implications of variation within an immunodominant CD8+ T-cell epitope of HIV-1. Christie NM, Willer DO, Lobritz MA, Chan JK, Arts EJ, Ostrowski MA, Cochrane A, Luscher MA, MacDonald KS. Virology. 2009 May 25;388(1):137-46

12. HIV-neutralizing immunoglobulin A and HIV-specific proliferation are independently associated with reduced HIV acquisition in Kenyan sex workers. Hirbod T, Kaul R, Reichard C, Kimani J, Ngugi E, Bwayo JJ, Nagelkerke N, Hasselrot K, Li B, Moses S; Kibera HIV Study Group., Broliden K. MacDonald KS, AIDS. 2008 Mar 30;22(6):727-35.

13. Monthly antibiotic chemoprophylaxis and incidence of sexually transmitted infections and HIV-1 infection in Kenyan sex workers: a randomized controlled trial. Kaul R, Kimani J, Nagelkerke NJ, Fonck K, Ngugi EN, Keli F, MacDonald KS, Maclean IW, Bwayo JJ, Temmerman M, Ronald AR, Moses S; Kibera HIV Study Group. JAMA. 2004 Jun ;291(21):2555-62.